A Phase II study of acute toxicity for Celebrex™ (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: Primary endpoint analysis of RTOG 0128

Gaffney, David K.; Winter, Kathryn; Dicker, Adam P.; Miller, Brigitte; Eifel, Patricia J.; Ryu, Janice; Avizonis, Vilija N.; Fromm, Mitchel; Greven, Kathryn M.

doi:10.1016/j.ijrobp.2006.08.002

Cited by 54 publications

(26 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical trials with specific Cox-2 inhibitors documented a significant reduction in adenoma formation in patients at high risk for CRC [76,77]. However, other clinical trials failed to show a benefit of including Cox-2 inhibitors to standard chemotherapeutic or radiotherapeutic regimens, for example, in advanced pancreatic adenocarcinoma or in cervical cancer [78,79]. In addition, due to an increased risk of cardiovascular complications, the clinical trials in CRC patients had to be terminated prematurely.…”

Section: Cox-2 Inhibitorsmentioning

confidence: 99%

Corrupt policemen: inflammatory cells promote tumor angiogenesis

Zumsteg

Christofori

2009

Current Opinion in Oncology

104

View full text Add to dashboard Cite

Inflammatory reactions coinciding with carcinogenesis can be visualized by the presence of specific bone marrow-derived, inflammatory cells in patients' peripheral blood. Recent findings suggest that such inflammatory fingerprints may better define the inflammatory nature of the primary malignancy and, thus, allow the design of therapeutic strategies targeting the protumorigenic immune cell stroma compartment.

show abstract

Section: Cox-2 Inhibitorsmentioning

confidence: 99%

Corrupt policemen: inflammatory cells promote tumor angiogenesis

Zumsteg

Christofori

2009

Current Opinion in Oncology

104

View full text Add to dashboard Cite

show abstract

“…Multiple cytotoxic and targeted agents have been added to cisplatin and radiation in an attempt to improve outcomes for patients with locally advanced cervical cancer [4][5][6][7][8][9][23][24][25][29][30][31]. Further improvements may require such strategies as the addition of chemotherapy or targeted therapy after chemoradiation.…”

Section: Discussionmentioning

confidence: 99%

A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study

Moore

Sill

Miller³

et al. 2012

Gynecologic Oncology

View full text Add to dashboard Cite

“…Gaffney et al 17 reported a significant rate of acute GI toxicity in 43% (33/77) of patients in the RTOG 0128 study using celecoxib. The most frequently observed grade 3 and 4 toxicity was hematologic toxicity (40/77).…”

Section: Discussionmentioning

confidence: 99%

“…Our lower rates of acute GI and hematologic toxicities might be due to differences in the disease stage of enrolled patients and chemotherapy regimens. The chemotherapy regimen used by Gaffney et al 17 was cisplatin at 75 mg/m 2 to a maximal dose of 150 mg with 5-fluorouracil. A prospective randomized study, which was conducted to compare monthly fluorouracil plus cisplatin and weekly cisplatin-based CCRT for cervical cancer, demonstrated that acute hematologic and GI toxicities developed more frequently in patients who received monthly fluorouracil and cisplatin-based CCRT.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Acute toxicity of cyclooxygenase-2 inhibitor rofecoxib as a radiosensitizer for concurrent chemoradiation in the treatment of uterine cervical cancer

et al. 2009

View full text Add to dashboard Cite

Objective: To evaluate the acute toxicity of rofecoxib during concurrent use with cisplatin-based chemoradiotherapy (CCRT) in patients with cervical cancer. Methods: We evaluated 67 FIGO stage IB2-IVA cervical cancer patients treated with CCRT between June 2002 and July 2004. The study group included patients who received rofecoxib (N=30) and the control group included patients who received CCRT only (N=37). The patients' medical records were retrospectively reviewed for patient characteristics, toxicity related to CCRT and treatment results. Results: There were no significant differences in toxicity between the two groups. The most common acute grade 3/4 toxicity was neutropenia (13.3% in the study group and 21.6% in the control group). Grade 3/4 late toxicity was observed in 2 (6.6%) patients in the study group and 3 (8.1%) in the control group. There was no treatment-related deaths in either group. Six (20.0%) patients in the study group had treatment failure. In the control group, 6 (16.2%) patients experienced treatment failure. Progression-free and overall survival was 55.8±4.2 and 59.0±2.8 months, respectively, in the study group, and 69.7±4.3 and 71.6±3.6 months, respectively, in the control group. There were no differences in progression-free and overall survival between the 2 groups. Conclusion: Our data indicate that rofecoxib, at a dose of 25 mg twice daily, has acceptable acute toxicity as a radiosensitizer during CCRT. Although rofecoxib was not efficacious as a radiosensitizer in the present study, the benefit of rofecoxib as a radiosensitizer should be further evaluated in a prospective study.

show abstract

A Phase II study of acute toxicity for Celebrex™ (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: Primary endpoint analysis of RTOG 0128

Cited by 54 publications

References 34 publications

Corrupt policemen: inflammatory cells promote tumor angiogenesis

Corrupt policemen: inflammatory cells promote tumor angiogenesis

A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study

Acute toxicity of cyclooxygenase-2 inhibitor rofecoxib as a radiosensitizer for concurrent chemoradiation in the treatment of uterine cervical cancer

Contact Info

Product

Resources

About